Answers are grounded in this paper and cite their sources.
A case report reveals unusual lymphocyte expansion following ciltacabtagene autoleucel, suggesting diagnostic considerations for multiple myeloma.
We report a case of delayed hypersensitivity dermatitis and an unusual lymphocyte expansion peaking at 45,000 cells/µL by Day +14 after ciltacabtagene autoleucel, a BCMA‐targeted CAR T therapy for multiple myeloma (MM). This marked post‐infusion lymphocytosis was initially mistaken for plasmacytosis but was confirmed by flow cytometry to be circulating CAR T cells. The lymphocytosis self‐resolved and was followed by complete remission. This case highlights that peripheral CAR T cell expansion may be mistaken for malignant plasmacytosis in the early post‐infusion period and underscores the critical role of flow cytometry in distinguishing CAR T cells from malignant plasma cells.
No takes yet. Share an insight, caveat, or question.
Shapiro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: